Exagen Inc. XGN
We take great care to ensure that the data presented and summarized in this overview for EXAGEN INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding XGN
View all-
Rtw Investments, LP New York, NY1.51MShares$8.35 Million0.07% of portfolio
-
Cowen And Company, LLC891KShares$4.92 Million0.07% of portfolio
-
Silvercrest Asset Management Group LLC New York, NY541KShares$2.99 Million0.01% of portfolio
-
Stonepine Capital Management, LLC Bend, OR534KShares$2.95 Million1.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA491KShares$2.71 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT490KShares$2.71 Million0.01% of portfolio
-
Morgan Stanley New York, NY482KShares$2.66 Million0.0% of portfolio
-
Perkins Capital Management Inc459KShares$2.53 Million1.39% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny176KShares$969,3110.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO170KShares$935,9320.01% of portfolio
Latest Institutional Activity in XGN
Top Purchases
Top Sells
About XGN
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Insider Transactions at XGN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 20
2024
|
Nmsic Co Investment Fund, L.P. |
SELL
Open market or private sale
|
Indirect |
200,000
-8.66%
|
$600,000
$3.3 P/Share
|
Nov 15
2024
|
Jeffrey G. Black Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
22,298
+7.51%
|
$44,596
$2.98 P/Share
|
Nov 14
2024
|
John Aballi President and CEO |
BUY
Open market or private purchase
|
Direct |
24,305
+3.4%
|
$48,610
$2.81 P/Share
|
Sep 01
2024
|
Jeffrey G. Black Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
225,000
+47.15%
|
-
|
May 16
2024
|
John Aballi President and CEO |
BUY
Open market or private purchase
|
Indirect |
40,401
+50.0%
|
$40,401
$1.92 P/Share
|
Mar 04
2024
|
Kamal Adawi CFO and Corporate Secretary |
SELL
Open market or private sale
|
Direct |
12,784
-2.52%
|
$12,784
$1.91 P/Share
|
Feb 29
2024
|
John Aballi President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
9,804
+1.61%
|
$9,804
$1.91 P/Share
|
Feb 20
2024
|
John Aballi President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
175,000
+22.85%
|
-
|
Feb 20
2024
|
Kamal Adawi CFO and Corporate Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+22.62%
|
-
|
Feb 06
2024
|
Kamal Adawi CFO and Corporate Secretary |
SELL
Open market or private sale
|
Direct |
6,738
-3.58%
|
$6,738
$1.95 P/Share
|
Oct 17
2023
|
John Aballi President and CEO |
SELL
Open market or private sale
|
Direct |
33,819
-7.52%
|
$33,819
$1.75 P/Share
|
Aug 31
2023
|
John Aballi President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
9,803
+2.13%
|
$19,606
$2.14 P/Share
|
Jun 15
2023
|
James L L Tullis > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
167
+0.01%
|
$501
$3.11 P/Share
|
Mar 02
2023
|
Kamal Adawi CFO and Corporate Secretary |
SELL
Open market or private sale
|
Direct |
3,667
-1.91%
|
$7,334
$2.3 P/Share
|
Mar 02
2023
|
Mark Hazeltine Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,667
-1.89%
|
-
|
Feb 27
2023
|
Mark Hazeltine Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+34.03%
|
-
|
Feb 27
2023
|
Kamal Adawi CFO and Corporate Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+34.25%
|
-
|
Feb 08
2023
|
Kamal Adawi CFO and Corporate Secretary |
SELL
Open market or private sale
|
Direct |
5,821
-5.95%
|
$11,642
$2.69 P/Share
|
Feb 08
2023
|
Mark Hazeltine Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,821
-5.84%
|
$11,642
$2.69 P/Share
|
Dec 08
2022
|
John Aballi President and CEO |
BUY
Open market or private purchase
|
Direct |
90,000
+16.98%
|
$180,000
$2.68 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 485K shares |
---|---|
Open market or private purchase | 87K shares |
Open market or private sale | 220K shares |
---|